Lucerastat

Drug Profile

Lucerastat

Latest Information Update: 26 Jul 2016

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Antihyperlipidaemics; Piperidines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fabry's disease
  • No development reported Lipid metabolism disorders

Most Recent Events

  • 21 Jul 2016 Actelion completes phase Ib trial in Fabry's disease
  • 30 Jun 2015 Phase-I clinical trials in Fabry's disease (unspecified route) before June 2015
  • 31 Dec 2012 Phase-I clinical trials in Lipid metabolism disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top